High residual platelet reactivity (PR) in patients on clopidogrel therapy is associated with thrombotic events after percutaneous coronary intervention (PCI) with drug-eluting stents. It is well documented that determining an optimal PR cut-off point helps to better predict major adverse cardiovascular events (MACE). In addition, determining the optimal PR cut-off point helps to sufficiently suppress the platelet aggregation to prevent thrombotic events after PCI. However, the measurements of platelet function in patients on clopidogrel therapy have indicated wide variability in P2Y12 inhibition level (1), which is relatively explicated by genetic polymorphisms encoding CYP2C19 as well as the hepatic enzyme CYP450. In this regard, several studies have selected different PR cut-off points to identify high-risk patients. For example, in a study with 660 patients, Nakamura et al. (2) found that the optimal platelet reactivity unit (PRU) cut-off point for preventing MACE after PCI is 262. In another study by Marcucci et al. Much inconsistency exists in the literature concerning the selection of optimal PR cut-off point in patients on clopidogrel therapy undergoing elective PCI. It important that the optimal PRU cut-off point in patients treated with clopidogrel has not been discussed in the 2011 American College of Cardiology (ACC) / American Heart Association Guideline for PCI (5). Therefore, selecting the optimal PRU cut-off point warrants further investigations. The optimal PRU cut-off point should be studied and integrated in the current clinical practice guidelines so that it becomes a standard of practice for PCI.
